Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002203 · ClinicalTrials.gov registry record · NA
A Study of Two Anti-HIV Drug Combinations
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002203 is a NA study that has completed, run by Glaxo Wellcome.
The verdict
NCT00002203, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI. This study also examines how well patients follow the dosing schedules for these drugs. Doctors believe that taking Combivir plus a PI may be as effective as taking 3TC plus ZDV plus a PI.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Lamivudine/Zidovudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002203
The ClinicalTrials.gov registry entry for NCT00002203 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002203 about?
NCT00002203 is a clinical study titled "A Study of Two Anti-HIV Drug Combinations". The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI. This study also examines how well patients follow the dosing schedules for these drugs...
What is the current status of trial NCT00002203?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002203?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Lamivudine/Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002203?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.